Nexus Investment Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$31.7M Sell
251,016
-3,706
-1% -$488K 4.14% 11
2026
Q1
$35.5M Sell
254,722
-3,102
-1% -$434K 4.96% 8
2025
Q4
$31.6M Sell
257,824
-1,200
-0.5% -$146K 4.31% 11
2025
Q3
$28.8M Buy
259,024
+21,220
+9% +$2.41M 4.08% 11
2025
Q2
$26.4M Sell
237,804
-3,905
-2% -$416K 3.94% 10
2025
Q1
$39M Buy
241,709
+1,896
+0.8% +$196K 4.41% 11
2024
Q4
$22.2M Sell
239,813
-43,250
-15% -$3.89M 2.22% 22
2024
Q3
$23.7M Sell
283,063
-5,355
-2% -$409K 2.33% 23
2024
Q2
$19.8M Sell
288,418
-1,060
-0.4% -$70.7K 2.08% 26
2024
Q1
$21.2M Sell
289,478
-500
-0.2% -$38.4K 2.04% 28
2023
Q4
$23.5M Sell
289,978
-1,990
-0.7% -$155K 2.45% 25
2023
Q3
$21.9M Buy
291,968
+455
+0.2% +$35K 2.47% 21
2023
Q2
$22.5M Sell
291,513
-1,955
-0.7% -$156K 2.45% 25
2023
Q1
$24.3M Sell
293,468
-750
-0.3% -$62.1K 2.69% 20
2022
Q4
$25.3M Buy
294,218
+15,425
+6% +$1.22M 2.85% 17
2022
Q3
$17.2M Buy
278,793
+2,875
+1% +$181K 2.14% 24
2022
Q2
$17.1M Sell
275,918
-37,550
-12% -$2.32M 1.96% 26
2022
Q1
$18.6M Buy
313,468
+2,950
+1% +$189K 1.96% 25
2021
Q4
$22.5M Sell
310,518
-1,800
-0.6% -$124K 2.29% 23
2021
Q3
$21.8M Sell
312,318
-3,078
-1% -$216K 2.36% 22
2021
Q2
$21.7M Buy
315,396
+4,525
+1% +$302K 2.24% 25
2021
Q1
$20.1M Buy
310,871
+18,655
+6% +$1.2M 2.29% 24
2020
Q4
$16.7M Buy
292,216
+1,275
+0.4% +$76.9K 2.15% 24
2020
Q3
$18.4M Buy
290,941
+1,975
+0.7% +$137K 2.78% 21
2020
Q2
$22.2M Sell
288,966
-18,300
-6% -$1.4M 3.42% 16
2020
Q1
$23M Buy
307,266
+4,450
+1% +$307K 4.05% 10
2019
Q4
$19.7M Buy
302,816
+29,775
+11% +$1.94M 2.69% 20
2019
Q3
$17.3M Sell
273,041
-3,250
-1% -$212K 2.46% 21
2019
Q2
$18.7M Buy
276,291
+6,820
+3% +$449K 2.59% 19
2019
Q1
$17.5M Buy
269,471
+6,225
+2% +$414K 2.59% 19
2018
Q4
$16.5M Buy
263,246
+1,823
+0.7% +$127K 2.88% 17
2018
Q3
$20.2M Buy
261,423
+32
+0% +$2.42K 2.89% 15
2018
Q2
$18.5M Buy
261,391
+2,050
+0.8% +$145K 2.75% 16
2018
Q1
$19.6M Buy
259,341
+700
+0.3% +$55.6K 3% 15
2017
Q4
$18.5M Buy
258,641
+225
+0.1% +$17.1K 2.75% 19
2017
Q3
$20.9M Buy
258,416
+3,300
+1% +$252K 3.27% 14
2017
Q2
$18.1M Buy
255,116
+1,950
+0.8% +$130K 2.94% 17
2017
Q1
$17.2M Buy
253,166
+18,150
+8% +$1.28M 2.93% 18
2016
Q4
$16.8M Buy
235,016
+21,500
+10% +$1.6M 2.86% 18
2016
Q3
$16.9M Buy
213,516
+11,675
+6% +$948K 3.08% 17
2016
Q2
$16.8M Buy
201,841
+2,991
+2% +$265K 3.21% 15
2016
Q1
$18.3M Buy
198,850
+8,300
+4% +$748K 3.45% 9
2015
Q4
$19.3M Buy
190,550
+1,875
+1% +$195K 3.87% 8
2015
Q3
$18.5M Buy
188,675
+900
+0.5% +$100K 3.88% 8
2015
Q2
$22M Sell
187,775
-2,265
-1% -$247K 4.27% 5
2015
Q1
$18.6M Sell
190,040
-900
-0.5% -$91.4K 3.67% 8
2014
Q4
$18M Sell
190,940
-6,300
-3% -$652K 3.37% 11
2014
Q3
$21M Sell
197,240
-2,075
-1% -$203K 3.96% 4
2014
Q2
$16.5M Buy
199,315
+10,650
+6% +$829K 3.07% 14
2014
Q1
$13.4M Buy
188,665
+12,500
+7% +$980K 2.61% 21
2013
Q4
$13.2M Buy
176,165
+35,650
+25% +$2.48M 2.66% 23
2013
Q3
$8.83M Buy
140,515
+134,515
+2,242% +$8.04M 1.88% 28
2013
Q2
$322K Buy
+6,000
New +$313K 0.07% 55

Other funds holding GILD

Nexus Investment Management's GILD Position: Q2 2026 in Review

Nexus Investment Management reduced its Gilead Sciences (GILD) stake by 1.5% in Q2 2026, selling an estimated $488K and leaving 251,016 shares worth $31.7M. The position accounts for 4.14% of the portfolio, ranked #11.

Nexus Investment Management first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $39M in Q1 2025. 1,032 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Nexus Investment Management held 251,016 shares of Gilead Sciences worth $31.7M as of Q2 2026.
  • Nexus Investment Management sold 3,706 Gilead Sciences shares in Q2 2026, an estimated $488K.
  • Gilead Sciences made up 4.14% of Nexus Investment Management's portfolio in Q2 2026, its #11 holding.
  • Nexus Investment Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Nexus Investment Management's Gilead Sciences position peaked at $39M in Q1 2025.
  • 1,032 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Nexus Investment Management's 13F filing for Q2 2026, filed 20 Jul 2026.